Literature DB >> 8777167

Expression of Bax in relation to Bcl-2 and other predictive parameters in breast cancer.

C Binder1, D Marx, L Binder, A Schauer, W Hiddemann.   

Abstract

BACKGROUND: It has been suggested that modification of the physiological susceptibility to induction of programmed cell death in transformed cells contributes to the pathogenesis of cancer. One of the major regulators of cell death is the bcl-2 family. In breast cancer, altered expression of Bcl-2 has been described. Distribution of its counterpart Bax and the differential expression pattern have still to be evaluated. PATIENTS AND METHODS: Bax expression was investigated by immunohistochemistry in 122 primary breast cancers. Results were correlated with expression of Bcl-2 and other variables of predictive value.
RESULTS: There was a positive association between Bax expression and histological grading, (over)expression of c-erbB-1 and -2 and proliferative activity. The correlation was most significant in cases where no concomitant Bcl-2 expression could be detected. In the same subgroup an inverse correlation with positivity for estrogen (and progesterone) receptors was observed. The presence of Bax was not significantly associated with either tumor type and size, nodal status or expression of c-erbB-3.
CONCLUSION: Expression of Bax was coupled with negative histopathological features, especially when expression of Bcl-2 was downregulated concomitantly. It may appear that alterations of the differential Bax/Bcl-2 expression pattern take part in deregulation of proliferation and loss of differentiation, thus playing an important role in malignant progression.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8777167     DOI: 10.1093/oxfordjournals.annonc.a010538

Source DB:  PubMed          Journal:  Ann Oncol        ISSN: 0923-7534            Impact factor:   32.976


  10 in total

Review 1.  Apoptosis: molecular mechanisms and implications for cancer chemotherapy.

Authors:  H J Guchelaar; A Vermes; I Vermes; C Haanen
Journal:  Pharm World Sci       Date:  1997-06

2.  Association of mitochondrial DNA 10398 polymorphism in invasive breast cancer in malay population of peninsular malaysia.

Authors:  Nadiah Tengku Baharudin; Hasnan Jaafar; Zafarina Zainuddin
Journal:  Malays J Med Sci       Date:  2012-01

3.  YB-1 represses AP1-dependent gene transactivation and interacts with an AP-1 DNA sequence.

Authors:  Shaija Samuel; Jean-Claude Twizere; Lori R Bernstein
Journal:  Biochem J       Date:  2005-06-15       Impact factor: 3.857

4.  Radish (Raphanus sativus L. leaf) ethanol extract inhibits protein and mRNA expression of ErbB(2) and ErbB(3) in MDA-MB-231 human breast cancer cells.

Authors:  Woo Kyoung Kim; Ji Hae Kim; Da Hee Jeong; Young Hee Chun; Sun Hee Kim; Kang Jin Cho; Moon-Jeong Chang
Journal:  Nutr Res Pract       Date:  2011-08-31       Impact factor: 1.926

Review 5.  New developments in cancer treatment with the novel thymidylate synthase inhibitor raltitrexed ('Tomudex').

Authors:  G Blackledge
Journal:  Br J Cancer       Date:  1998       Impact factor: 7.640

6.  Lower expression of Bax predicts poor clinical outcome in patients with glioma after curative resection and radiotherapy/chemotherapy.

Authors:  Pei-Guo Wang; Yu-Ting Li; Yi Pan; Zhen-Zhu Gao; Xu-Wen Guan; Li Jia; Feng-Ting Liu
Journal:  J Neurooncol       Date:  2018-11-16       Impact factor: 4.130

Review 7.  Revealing the Roles of MOAP1 in Diseases: A Review.

Authors:  Yanfang Su; Weixia Wang; Xianfang Meng
Journal:  Cells       Date:  2022-03-04       Impact factor: 6.600

8.  Inorganic sulfur reduces cell proliferation by inhibiting of ErbB2 and ErbB3 protein and mRNA expression in MDA-MB-231 human breast cancer cells.

Authors:  Ae Wha Ha; Kyung Hee Hong; Hee Sun Kim; Woo Kyoung Kim
Journal:  Nutr Res Pract       Date:  2013-04-01       Impact factor: 1.926

9.  Association of XRCC3, XRCC4, BAX, and BCL-2 Polymorphisms with the Risk of Breast Cancer.

Authors:  Emre Ozoran; Fadime Didem Can Trabulus; Duygu Erhan; Bahadir Batar; Mehmet Guven
Journal:  Int J Breast Cancer       Date:  2022-03-14

10.  A Novel Ruthenium-Fluvastatin Complex Downregulates SNCG Expression to Modulate Breast Carcinoma Cell Proliferation and Apoptosis via Activating the PI3K/Akt/mTOR/VEGF/MMP9 Pathway.

Authors:  Wei Liang; Junfeng Shi; Haiyan Xia; Xiaowei Wei
Journal:  Oxid Med Cell Longev       Date:  2021-06-07       Impact factor: 6.543

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.